Think of the first month as your adjustment phase , not your finish line
Cairns, R
Funding This work was supported by grants from NIH (K01 DK105108), American Heart Association (17GRNT33670485), American Association of Immunologists (CIIF-8745), Boehringer Ingelheim (IIS2015-10485), and National Natural Science Foundation of China (81670431 and 81671544)
We found that the levels of CXCL10 and its downstream effectors, p-JNK, COL1A1, and p-AKT, significantly increased in M38 or B16 group, WCV significantly reduced their levels close to control in VM38 or VB16 group, and PD-1 had no obvious impacts in PM38 or PB16 group (Fig
The study assessed drug utilization and temporal changes in treatment options (e.g., SGLT2i, GLP-1 RA) in adults with CKD and type 2 diabetes regarding two time periods: an earlier period (1 January 201230 June 2021) and a later period after the US approval of finerenone (9 July 202130 September 2023), with the latter period representing updated treatment guidelines, changes to CKD drug labeling (e.g., SGLT2i), and the availability of new CKD-protective medications (ESM Fig